Drug Approval | March 09, 2024
Dishman Carbogen Amcis updates on USFDA inspection at its Bavla facility
The inspection was concluded with few procedural observations
The inspection was concluded with few procedural observations
The company's Bavla site was successfully jointly inspected by the EDQM and Italian Medicines Agency (AIFA)
Dishman Carbogen Amcis has reported total income of Rs. 729.91 crores during the period ended June 30, 2023
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
Dishman Carbogen Amcis has reported consolidated financial results for the period ended December 31, 2021
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)